ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...

Artificial intelligence (AI) is reshaping the way businesses operate in the retail and e-commerce spaces. From streamlining ...

BCG highlights how governments are reshaping energy policies to balance sustainability, security and affordability, focusing ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

Business leaders are ambitious about agentic AI but have legitimate concerns about data privacy, security, and compliance.

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

GenAI could be India’s next trillion-dollar opportunity, transforming IT services the way cloud computing once did. But India ...

The Federal Maritime Commission wants to know whether foreign countries and their shipping companies are causing supply chain ...